Repurposed small molecule toxin inhibitors neutralise a diversity of venoms from the Neotropical viperid snake genus Bothrops

This study demonstrates that repurposed small-molecule inhibitors targeting metalloproteinases and phospholipases effectively neutralize a diverse range of venoms from the Neotropical *Bothrops* snake genus, suggesting their potential as valuable early interventions for snakebite treatment.

The Gist

The Big Picture: A New Hope for Snakebite Victims

Imagine a snakebite as a biological house fire. When a venomous snake bites you, it doesn't just inject poison; it injects a chaotic mix of "chemical arsonists" that start fires in your blood, destroy your muscles, and stop your heart.

Currently, the only way to put out these fires is antivenom. Think of antivenom as a custom-made fire brigade. You have to call them, they have to travel to you, and they are trained to fight specific types of fires (specific snake species). But here's the problem:

1. They are slow: In remote areas, it can take hours for the fire brigade to arrive. By then, the house is already burning down.
2. They are picky: If the fire is slightly different than what they were trained for, they might not be able to stop it.
3. They are expensive and fragile: They need to be kept cold (like ice cream) and cost a lot of money.

This study asks a bold question: What if, instead of waiting for a custom fire brigade, we could use universal fire extinguishers that are already sitting on the shelf in a pharmacy?

The "Repurposed" Idea

The scientists looked at drugs that were already approved by doctors for other things (like treating cancer or arthritis). They asked: "Can we repurpose these existing drugs to stop snake venom?"

It's like realizing that a broom (designed for sweeping floors) can also be used to push a heavy box if you angle it right. You don't need to invent a new tool; you just need to use an old one in a new way.

The Enemy: The "Bothrops" Snake Family

The researchers focused on the Bothrops genus of snakes, which are the most dangerous snakes in Central and South America. These snakes are notorious for causing:

• Bleeding: Making your blood turn into jelly so it can't clot.
• Tissue Death: Rotting the flesh around the bite.
• Muscle Damage: Destroying muscle tissue.

The venom of these snakes is a "cocktail" of different weapons. The study found that while every snake species has a slightly different recipe, they all rely heavily on three main types of "arsonists":

1. The Metalloproteinases (SVMPs): These are the heavy hitters that chew up blood vessels and cause massive bleeding.
2. The Phospholipases (PLA2s): These destroy cell membranes, causing muscle death and inflammation.
3. The Serine Proteases (SVSPs): These mess up the blood clotting system.

The Experiment: Testing the Fire Extinguishers

The team took seven different types of Bothrops venom and tested them against a lineup of repurposed drugs in a lab. They wanted to see if these drugs could neutralize the venom's ability to cause damage.

Here is what they found:

1. The Heavy Hitters (SVMP Inhibitors)

• The Drugs: Marimastat and DMPS.
• The Analogy: Imagine the venom's bleeding enzymes as power saws cutting through your blood vessels. Marimastat and DMPS act like super-strong glue that jams the saw blades instantly.
• The Result: These drugs worked incredibly well. They stopped the bleeding effects in all the different snake venoms tested. Even better, when tested in a live model (chicken eggs), these drugs saved the embryos from dying, even when the venom was strong enough to kill them otherwise.
• The Star: Marimastat was the MVP. It worked fast, worked on all snakes, and is already known to be safe for humans.

2. The Muscle Protectors (PLA2 Inhibitor)

• The Drug: Varespladib.
• The Analogy: If the venom is a swarm of mosquitoes attacking your cells, Varespladib is a net that catches them all before they can bite.
• The Result: This drug was a "super-net." It neutralized the muscle-damaging enzymes in every single snake venom tested, even though the snakes had different amounts of these enzymes. This is huge because antivenoms often fail to stop muscle damage.

3. The "Maybe" Drug (SVSP Inhibitor)

• The Drug: Nafamostat.
• The Analogy: This drug is like a sledgehammer. It can stop the clotting enzymes, but it's so heavy that it breaks the table (the patient's own blood clotting system) in the process.
• The Result: It was too messy. It stopped the venom, but it also made the blood too thin, which is dangerous. The scientists decided this one needs more work before it's ready for prime time.

Why This Matters: The "Paradigm Shift"

The most exciting part of this paper isn't just that the drugs work; it's how they could change the future of snakebite treatment.

Currently, if you get bitten in the Amazon, you have to wait hours for a truck to bring you to a hospital with a fridge full of antivenom.

• The New Vision: Imagine a community health worker or even a local shop having a small box of pills.
• The Benefit: These pills (like Marimastat) could be:
  • Oral: You can swallow them (no needles needed).
  • Stable: They don't need a fridge (they won't melt in the tropical heat).
  • Fast: You can take them immediately after the bite, stopping the damage before it spreads.
  • Universal: One pill works for many different snakes, not just one specific species.

The Conclusion

The study concludes that repurposed drugs are a game-changer. Specifically, Marimastat (for bleeding) and Varespladib (for muscle damage) show incredible promise.

They aren't a perfect replacement for antivenom yet, but they offer a first line of defense. They could be the "fire extinguisher" you grab immediately after the bite, buying you precious time until the "fire brigade" (antivenom) arrives. This could save thousands of lives in the remote corners of the world where snakebites are most common.

In short: We might not need to invent new magic bullets; we just need to realize that the bullets we already have in the cabinet can save lives if we aim them at the right target.

Technical Summary

1. Problem Statement

Snakebite envenoming is a neglected tropical disease causing over 100,000 deaths annually, with significant morbidity. Current treatment relies on antivenoms (polyclonal antibodies), which suffer from limitations including:

• Geographic and species specificity: Venom composition varies significantly between species, populations, and individuals, rendering some antivenoms ineffective against local variants.
• Logistical constraints: Antivenoms require cold-chain storage, intravenous (IV) administration in tertiary care, and have a high risk of adverse reactions (e.g., anaphylaxis).
• Treatment delays: In remote Neotropical regions (Central and South America), the time between a bite and medical care often exceeds 5 hours, leading to severe tissue damage and systemic toxicity.

The genus Bothrops (pit vipers) is responsible for the majority of snakebites in the Neotropics. These venoms are complex cocktails dominated by three enzyme families: Snake Venom Metalloproteinases (SVMPs), Phospholipases A2 (PLA2s), and Snake Venom Serine Proteases (SVSPs). The study aims to evaluate repurposed small-molecule drugs as broad-spectrum, orally bioavailable alternatives to antivenoms for treating Bothrops envenoming.

2. Methodology

The researchers evaluated a panel of repurposed drugs against seven distinct Bothrops venoms (B. alternatus, B. asper, B. atrox, B. jararaca, B. lanceolatus, B. moojeni, B. neuwiedi) using a multi-tiered approach:

• Venom Characterization:

  • SDS-PAGE: To visualize protein composition and molecular weight distribution.
  • Enzymatic Assays: Kinetic assays measured specific activities of SVMPs (fluorogenic substrate), PLA2s (colorimetric substrate), and SVSPs (chromogenic substrate).
  • Phenotypic Assays: Bovine plasma coagulation assays and human whole blood thromboelastography (TEG) to assess procoagulant/anticoagulant effects.

• Drug Screening:

  • SVMP Inhibitors: Matrix metalloproteinase inhibitors (MMPis) including marimastat, prinomastat, batimastat, tanomastat, XL-784, CTS-1027; and metal chelators DMPS and dimercaprol.
  • PLA2 Inhibitor: Varespladib.
  • SVSP Inhibitor: Nafamostat.
  • Controls: Doxycycline (included as a negative control for SVMPs).
  • Metrics: Dose-response curves were generated to calculate EC50 values for enzymatic inhibition and coagulation restoration.

• In Vivo Validation:

  • Chicken Embryo Model: A vascularized in vivo model using fertilized chicken eggs. Embryos were dosed with B. atrox venom (20 µg) followed by topical application of inhibitors (marimastat, DMPS, or nafamostat) to assess protection against vascular destruction and lethality over 6 hours.

3. Key Results

Venom Diversity

• Significant interspecies and intraspecies variation was observed in toxin composition and enzymatic activity.
• SVMP Activity: Generally high across all species, with B. jararaca and B. lanceolatus showing the highest activity.
• PLA2 Activity: Highly variable; B. alternatus showed negligible activity, while B. lanceolatus and B. atrox were highly active.
• SVSP Activity: Variable, with B. moojeni and B. lanceolatus exhibiting the highest activity.
• Coagulation: All venoms induced procoagulant effects, though potency varied.

Drug Efficacy (In Vitro)

• SVMP Inhibitors (Marimastat & DMPS):
  • Marimastat: Demonstrated pan-species nanomolar inhibition of SVMP activity (EC50: 1.8–10.6 nM) and effectively neutralized procoagulant effects in plasma and human whole blood (TEG).
  • DMPS: Showed sub-micromolar potency (EC50: ~200 nM – 3 µM) in enzymatic assays, generally less potent than marimastat in vitro, but showed surprising efficacy in specific coagulation contexts (e.g., B. lanceolatus).
• PLA2 Inhibitor (Varespladib):
  • Exhibited potent pan-species inhibition of PLA2 activity (EC50: 0.2–1.6 nM).
  • However, it had minimal effect on the procoagulant phenotype of the venoms, confirming that coagulopathy in Bothrops is primarily driven by SVMPs, not PLA2s.
• SVSP Inhibitor (Nafamostat):
  • Showed weak inhibition of SVSP activity (<80% even at 10 µM).
  • Possessed inherent anticoagulant properties that interfered with assay interpretation.
  • Combination therapy (Marimastat + Nafamostat) showed additive effects in B. jararaca but not B. atrox, suggesting SVSPs play a secondary role in the lethality of these specific venoms compared to SVMPs.

In Vivo Protection (Chicken Embryo Model)

• Marimastat: Provided dose-dependent protection. At 5 µg, it achieved 100% survival against B. atrox venom, completely preventing vascular destruction and lethality.
• DMPS: Despite lower in vitro potency, it provided 100% survival at 1.0 µg and 5.0 µg doses, highlighting a disconnect between in vitro enzymatic inhibition and in vivo therapeutic efficacy for metal chelators.
• Nafamostat: Showed modest survival rates (40–60%) but no statistical significance compared to the venom-only control, reinforcing that SVSP inhibition alone is insufficient for Bothrops envenoming.

4. Key Contributions

• Pan-Species Validation: Demonstrated that specific repurposed drugs (marimastat, varespladib, DMPS) can neutralize the enzymatic activities of a diverse range of Bothrops venoms, overcoming the variability that plagues antivenom efficacy.
• Mechanistic Insight: Clarified that while PLA2s are abundant, SVMPs are the primary drivers of coagulopathy and lethality in Bothrops envenoming, making them the critical target for small-molecule intervention.
• In Vitro/In Vivo Discrepancy: Highlighted that metal chelators like DMPS may appear less potent in vitro but can be highly effective in vivo, suggesting that triaging drugs based solely on enzymatic EC50 values may be misleading.
• Therapeutic Strategy: Provided strong preclinical evidence for a "cocktail" approach or the prioritization of SVMP inhibitors as a first-line, oral, community-based intervention.

5. Significance

This study provides a robust rationale for advancing marimastat and DMPS into clinical trials for snakebite treatment in the Neotropics.

• Paradigm Shift: It supports the transition from IV antivenoms to oral, small-molecule therapeutics that can be administered rapidly in community settings, potentially reducing the time-to-treatment from hours to minutes.
• Safety and Cost: These drugs have established safety profiles, are low-cost to manufacture, and do not require cold-chain storage.
• Future Direction: The authors advocate for immediate progression to murine preclinical models and subsequent Phase II clinical trials, particularly for B. atrox envenoming, to validate these findings in a mammalian system and ultimately save lives in regions currently underserved by effective antivenom distribution.